Wyeth's Success in China's Regulated Market

Strategic Insights -

Foreign pharmaceutical companies have struggled to navigate China's heavily regulated and bureaucratic market, but US-based Wyeth has found a way to thrive. By focusing on infant nutrition products and leveraging the mainland's low-cost laboratory capabilities, Wyeth has generated significant revenue and expanded its presence. The company's Asia-Pacific vice-president, Steve Higgins, attributes the success to the demand for high-quality products and the cost savings associated with conducting clinical trials and lab work on the mainland.

Key Takeaways:

  • Wyeth has achieved significant success in China's highly regulated market by focusing on infant nutrition products, with a market worth approximately US$100 million last year.
  • The company has established two factories on the mainland, operates in over 25 cities, and employs 1,300 people.
  • Wyeth's Asia-Pacific vice-president, Steve Higgins, estimates that the costs associated with patient trials on the mainland are almost 90% cheaper than in the US.
  • The company has conducted several clinical trials on mainland patients as part of the US FDA's approval process for new drugs, including the injectable broad-spectrum antibiotic Tygacil.
  • Wyeth is considering shifting some of its biological and chemical laboratory work to the mainland, where facilities and technicians are significantly cheaper than in the US.
  • The company has avoided major issues with counterfeiting, but Higgins notes that the danger lies in the potential harm to patients and the damage to its reputation.

Statistics:

  • China's baby food market was worth approximately US$100 million last year (Source: Steve Higgins, Asia-Pacific vice-president, Wyeth).
  • Wyeth's China business is derived mostly from infant nutrition products, with the company boasting two factories on the mainland and operating in over 25 cities.
  • The costs associated with patient trials on the mainland are almost 90% cheaper than in the US (Source: Steve Higgins, Wyeth).
  • Wyeth has employed 1,300 people in mainland China.
  • The company has conducted several clinical trials on mainland patients, including the injectable broad-spectrum antibiotic Tygacil.

Sources:

  • Steve Higgins, Asia-Pacific vice-president, Wyeth (exact quotes and information).
  • (No external sources mentioned in the original text).